Physician

Andrew Jason Lipman, M.D.

According to 2025 Medicare claims, Andrew Lipman, M.D. (NPI: 1780654889) practices hematology/oncology in the Naples-Marco Island, FL market, with the plurality of this provider's patient population coming from Collier, FL. This provider's primary affiliated billing organization is FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (NPI: 1760590962; TIN: 65-0825133) and primary practice location at 34105-5020.

Lipman's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,765 traditional Medicare patients, billed 541,662 HCPCS/CPT codes, and received $9,011,292 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,424 prescription claims across 297 beneficiaries totaling $7,380,301 in drug costs, led by Revlimid (Lenalidomide). DME data shows 80 claims. Open Payments data shows 137 records totaling $3,169. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved from a lower plateau to a higher plateau, from $4,723,884 to $9,011,292. Similarly, Part D prescription costs have moved from a lower plateau to a higher plateau, from $2,028,483 to $7,380,301. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	2,165	441,639	$4,723,884
2016	1,964	408,838	$5,299,890
2017	2,015	398,451	$5,277,662
2018	2,155	560,189	$7,178,324
2019	2,041	699,077	$8,475,537
2020	2,058	656,928	$9,923,968
2021	1,872	668,036	$11,354,297
2022	1,699	652,405	$9,867,958
2023	1,715	562,928	$9,341,157
2024	1,765	541,662	$9,011,292

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	279	1,225	$2,028,483
2016	266	1,208	$2,080,979
2017	264	1,140	$2,761,826
2018	272	1,194	$3,789,247
2019	276	1,174	$4,634,206
2020	276	1,269	$5,946,708
2021	308	1,495	$8,063,144
2022	306	1,390	$7,548,964
2023	323	1,538	$7,471,953
2024	297	1,424	$7,380,301

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	58	317	$42,687
2016	N/R	113	$5,250
2017	N/R	94	$8,327
2018	N/R	30	$1,911
2019	11	73	$5,326
2020	N/R	11	$751
2021	N/R	29	$633
2022	11	108	$3,057
2023	N/R	34	$1,531
2024	11	80	$1,115

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	1,079	2,395	$97
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	845	1,621	$13
96372	Injection of drug or substance under skin or into muscle	400	1,560	$11
36415	Insertion of needle into vein for collection of blood sample	1,437	5,428	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	1,417	5,634	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	112	3,017	$1,788,854
Imbruvica	Ibrutinib	62	1,736	$1,012,547
Xtandi	Enzalutamide	67	2,010	$780,360
Pomalyst	Pomalidomide	28	784	$612,991
Calquence	Acalabrutinib Maleate	36	1,080	$528,300

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	34	$482
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	32	$389
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	11	14	$245

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	137	$3,169	Janssen Biotech, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Andrew Jason Lipman, M.D.?

Tedicare shows public-source Medicare data for Andrew Jason Lipman, M.D. (NPI 1780654889), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Andrew Jason Lipman, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Andrew Jason Lipman, M.D.?

Andrew Jason Lipman, M.D. is linked to FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (billing NPI 1760590962) in the available physician profile data.

Does Andrew Jason Lipman, M.D. have Open Payments data?

Andrew Jason Lipman, M.D. has 137 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.